Skip to content
Whale Atlas — Follow the signal.
Home
FULL RECORDS
All Congress filingsSearch insider filingsEarnings calendarWatchlist
MORE TOOLS
Gold IntelligenceSilver IntelligencePeopleCharts & technicalsCompany financialsOfficial newsMy saved workspace
YOUR RESEARCH
HomeAll Congress filingsSearch insider filings
More research tools
ExploreGold IntelligenceSilver IntelligencePeopleInvestigate an ideaCharts & technicalsMore evidenceCompany financialsOfficial newsMy research & helpWatchlistMy saved workspaceLearn the basicsHow signals workData & coverage
RESOURCES
LearnMethodologyData sources
Built on public evidence.

Primary sources. Clear reasoning.
No black boxes.

Our approach
Public research workspacev1.0

Loading data…

CongressSearchHomeWatchlist
© 2026 Whale AtlasFree public-filing research. Not financial advice. By using this site you agree to the Terms of Use.
FAQCompare trackersMethodologyData & correctionsTermsPrivacy
LOOK INSIDE THE BUSINESS

Company financials.

Explore company-wide revenue, income and balance-sheet facts directly from SEC filings.

View NMTC insider activity ↗

NMTCNEUROONE MEDICAL TECHNOLOGIES Corp

THE LATEST REPORTED YEAR

The company reported a loss.

$3.61M net loss for the year ended September 30, 2025. These are reported results, not a forecast or a stock recommendation.

Revenue$9.1MYear ended September 30, 2025
Profit or loss-$3.61MYear ended September 30, 2025
Cash from the business-$2.84MYear ended September 30, 2025
Total assets$6.19MAs of June 30, 2026
Total liabilities$2.42MAs of June 30, 2026
Cash & equivalents$2.05MAs of June 30, 2026
THE BUSINESS BEHIND THE TICKER

Revenue, over time.

Latest-filed standard financial facts · USD

$1.17K
2010-12
$5.4K
2011-12
$921
2012-12
$178.15K
2021-09
$171.17K
2022-09
$1.95M
2023-09
$3.45M
2024-09
$9.1M
2025-09

Bars show magnitude; labels retain the sign. Each observation covers a reported annual period of 330–400 days; transition years can differ.

From the filing

Reported periods can differ from calendar years. Later filings may restate earlier figures. These are company-wide facts; product and geographic revenue segments are not included.

Reported periodReported valueFiledSource
October 1, 2024 – September 30, 2025$9,097,692December 17, 202510-K ↗
October 1, 2023 – September 30, 2024$3,453,003December 17, 202510-K ↗
October 1, 2022 – September 30, 2023$1,952,441December 17, 202410-K ↗
October 1, 2021 – September 30, 2022$171,169December 15, 202310-K ↗
October 1, 2020 – September 30, 2021$178,146December 22, 202210-K ↗
January 1, 2012 – December 31, 2012$921April 11, 201310-K ↗
January 1, 2011 – December 31, 2011$5,398April 11, 201310-K ↗
January 1, 2010 – December 31, 2010$1,167March 28, 201210-K ↗
Source and calculation details

One standard US-GAAP or IFRS concept is selected per metric, using USD only. Annual durations must be 330–400 days. Quarterly durations must be 70–110 days; year-to-date totals are excluded, and fourth quarters are never inferred by subtraction. Cash-flow quarters can therefore be sparse. Conflicting values filed on the same day are excluded. Latest-filed values are used, so these observations must not be treated as facts known in an earlier backtest.

Concept: us-gaap:Revenues · Retrieved October 14, 2026

Response SHA-256: dec08ad6d59f8d84b3a6db4a6ff83df3a276b794fed82089495b0788055433dd

SEC company facts

Company-wide USD figures from SEC filings. Each card keeps its own reporting date; later filings can revise earlier results.